



FSN Ref: Dale 850-20230320

FSCA Ref: CAP-20230302-1

Date: 2023/03/21



Urgent Field Safety Notice
Dale 850 Sterile Catheter Securement Device

For Attention of*: Dale Medical Products, Inc. Customers

Contact details of local representative (name, e-mail, telephone, address etc.)*

Dale Medical Products, Inc., 40 Kenwood Circle, Suite 7, Franklin, MA 02038, USA
Raymond Gruneberg, 508-316-4608, r.gruneberg@dalemed.net

Urgent Field Safety Notice (FSN)
Dale 850 Sterile Catheter Securement Device
Potential to be Not Sterile


1. Information on Affected Devices*	
1.	<p style="text-align: center;">1. Device Type(s)*</p> <div style="display: flex; justify-content: space-around;">   </div> <p style="text-align: center;">Adhesive backed sterile catheter securement device</p>
1.	<p style="text-align: center;">2. Commercial name(s)*</p> <p>Dale IV, Arterial and Mid-Line Catheter Securement Device</p>
1.	<p style="text-align: center;">3. Unique Device Identifier(s) (UDI-DI)</p> <p>0080020200124</p>
1.	<p style="text-align: center;">4. Primary clinical purpose of device(s)*</p> <p>Used to hold IV Catheters in place with a skin friendly adhesive</p>
1.	<p style="text-align: center;">5. Device Model/Catalogue/part number(s)*</p> <p>Dale 850</p>
1.	<p style="text-align: center;">6. Affected serial or lot number range</p> <p>LOT Number 216545</p>

2. Reason for Field Safety Corrective Action (FSCA)*	
2.	<p style="text-align: center;">1. Description of the product problem*</p> <p>Sterility of the product cannot be stated by our Notified Body, MedCert in Germany due to a change to the sterilizing facility location.</p>
2.	<p style="text-align: center;">2. Hazard giving rise to the FSCA*</p> <p>As noted, although the devices were sterilized, it cannot be stated and in the worst case the devices may not be sterile.</p>

2.	3. Probability of problem arising The probability of the device not being sterile is extremely low, as the lot went through the prescribed sterilization cycle with the Gamma Dosimetry Record for the lot provided with no excursions noted. Further, samples from the lot were also used for a sterilization dose audit which substantiated the stated dose for this production lot.
2.	4. Predicted risk to patient/users Dale Medical predicts no risk to patients because the devices were sterilized to the prescribed dose of 25-40 kyg by our contracted sterilization company. Our normal location was closed for preventive maintenance, so the devices were sent to a different location that was not documented in our sterilization validation; therefore TECHNICALLY, sterility cannot be stated.
2.	5. Background on Issue The device history records for this lot 216545 was being reviewed by our Notified Body during our annual ISO 13485 surveillance audit and the change of the sterilization location was noted and documented.

3. Type of Action to mitigate the risk*			
3.	<p>1. Action To Be Taken by the User*</p> <p> <input checked="" type="checkbox"/> Identify Device <input checked="" type="checkbox"/> Quarantine Device <input checked="" type="checkbox"/> Return Device <input checked="" type="checkbox"/> Destroy Device </p> <p> <input type="checkbox"/> On-site device modification / inspection <input type="checkbox"/> Follow patient management recommendations <input type="checkbox"/> Take note of amendment / reinforcement of Instructions For Use (IFU) <input type="checkbox"/> Other <input type="checkbox"/> None </p> <p>The devices are being recalled so they may be returned to Dale Medical or destroyed in the field as documented through correspondence with Dale Medical</p>		
3.	<table border="1" style="width: 100%;"> <tr> <td style="width: 35%;">2. By when should the action be completed?</td> <td style="text-align: right;">Specify where critical to patient/end user safety. 28 April, 2023</td> </tr> </table>	2. By when should the action be completed?	Specify where critical to patient/end user safety. 28 April, 2023
2. By when should the action be completed?	Specify where critical to patient/end user safety. 28 April, 2023		
3.	<table border="1" style="width: 100%;"> <tr> <td style="width: 70%;">3. Is customer Reply Required? * (If yes, form attached specifying deadline for return)</td> <td style="text-align: center;">Yes</td> </tr> </table>	3. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes		
3.	<p>4. Action Being Taken by the Manufacturer*</p> <p> <input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> Other <input type="checkbox"/> None </p> <p>Recall letters were provided to the two affected customers in Italy and Slovenia with details of the quantity of devices and date the devices were shipped to them by Dale Medical.</p>		
3.	<table border="1" style="width: 100%;"> <tr> <td style="width: 35%;">5. By when should the action be completed?</td> <td style="text-align: center;">28 April, 2023</td> </tr> </table>	5. By when should the action be completed?	28 April, 2023
5. By when should the action be completed?	28 April, 2023		

3.	6. Is the FSN required to be communicated to the patient /lay user?	No
----	---	----

4. General Information*		
4.	1. FSN Type*	New
4.	2. Further advice or information already expected in follow-up FSN? *	No
4.	3. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Dale Medical Products, Inc.
	b. Address	40 Kenwood Circle, Franklin, MA, USA
	c. Website address	www.dalemed.com
4.	4. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *	
4.	5. List of attachments/appendices:	
4.	6. Name/Signature	

Transmission of this Field Safety Notice	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate)</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*</p>

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.